Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04079088 (ClinicalTrials.gov)	June 30, 2021	3/9/2019	Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-ß1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)	A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 or Glatiramer Acetate Therapies in Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: Placebo;Drug: BIIB061;Biological: Interferon-beta1;Drug: Glatiramer acetate	Biogen	NULL	Not yet recruiting	18 Years	55 Years	All	300	Phase 2	NULL
2	NCT00219908 (ClinicalTrials.gov)	July 1999	16/9/2005	Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis	Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b	Relapsing-Remitting Multiple Sclerosis	Drug: Mitoxantrone	Rennes University Hospital	Bayer;Wyeth is now a wholly owned subsidiary of Pfizer;Farmades, Italy	Terminated	18 Years	45 Years	Both	124	Phase 2	France;Italy